The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 352:2233-2235 May 26, 2005 Number 21
NextNext

Targeting Biologic Markers in Asthma — Is Exhaled Nitric Oxide the Bull's-Eye?
Aaron Deykin, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Smith, A. D.
-PubMed Citation
Clinicians caring for patients with asthma need help. Asthma affects approximately 27 million persons in the United States. Despite the availability of effective therapies, asthma remains a source of significant morbidity and use of health care resources.1 National and international guidelines recommend that patients with persistent symptoms use inhaled corticosteroids as first-line therapy. On the basis of findings such as daytime or nighttime symptoms and impaired pulmonary function (as measured both at home and in the clinic), these guidelines also provide algorithms for increasing the doses of these medicines and adding other treatments.2,3,4 However, the practical application of these recommendations . . . [Full Text of this Article]


Source Information

From the Department of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.